Please use this identifier to cite or link to this item:
|Title:||A disease haplotype for advanced nephropathy in type 2 diabetes at the ACE locus||Authors:||Ng, D.P.K.
|Keywords:||ACR, albumin-to-creatinine ratio
CRF, chronic renal failure
ESRD, end-stage renal disease
MAF, minor allele frequency
|Issue Date:||Sep-2006||Citation:||Ng, D.P.K., Placha, G., Choo, S., Chia, K.-S., Warram, J.H., Krolewski, A.S. (2006-09). A disease haplotype for advanced nephropathy in type 2 diabetes at the ACE locus. Diabetes 55 (9) : 2660-2663. ScholarBank@NUS Repository. https://doi.org/10.2337/db06-0496||Abstract:||Previous investigations of the ACE gene as a susceptibility factor for diabetic nephropathy have primarily focused on its insertion/deletion (Ins/Del) polymorphism. In a departure from these earlier studies, we used three tagging markers (A-5466C, T-3892C, and Ins/Del) at the ACE locus to test for disease haplotype associations. A case-control study design was used where case subjects were type 2 diabetic patients with advanced diabetic nephropathy, as indicated by the presence of proteinuria or chronic renal failure/end-stage renal disease, while control subjects were normoalbuminuric, despite >6 years of diabetes. None of the individual markers showed significant disease association when considered on their own. However, haplotype analyses revealed a near doubling in the prevalence of the A.T.D risk haplotype in case subjects (0.136) compared with control subjects (0.075) (P = 0.009), thus providing first evidence for a disease haplotype for advanced diabetic nephropathy at the ACE locus. © 2006 by the American Diabetes Association.||Source Title:||Diabetes||URI:||http://scholarbank.nus.edu.sg/handle/10635/108228||ISSN:||00121797||DOI:||10.2337/db06-0496|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 15, 2020
WEB OF SCIENCETM
checked on Jan 8, 2020
checked on Jan 18, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.